“BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA”, Mediterr J Hematol Infect Dis, vol. 8, p. e2016011, Feb. 2016, doi: 10.4084/mjhid.2016.011.